Utah Medical Products (UTMD) Q3 Earnings Defy Revenue Drop

Utah Medical Products walked into this Q3 2026 earnings release with a mixed setup. The share price has drifted slightly over the past month and edged down another 1.1% to about $74 after the numbers hit. That modest pullback masks a key point. Profitability remains the anchor of the story, with Q3 net income at $2.8m on revenue of $8.6m, a level that keeps margins relatively high for a medical device manufacturer.

For anyone following this stock as a steady earner rather than a high-growth bet, the quarter was about one thing: margin resilience quietly beat the share price reaction.

Like Utah Medical Products' high margins but want a wider set of profitable, steady earners to compare it with? Screen for peers that combine robust profitability with cleaner balance sheets using our list of solid balance sheet and fundamentals stocks (25 results).

Q3 2026 Earnings Summary

• Revenue (Q3 2026 vs. Q3 2025): US$8.621m vs. US$9.812m (top line declined 12.1%)
• Net Income (Excl. Extra Items, Q3 2026 vs. Q3 2025): US$2.787m vs. US$2.631m (profit rose 5.9%)
• Basic EPS (Q3 2026 vs. Q3 2025): US$0.87632 vs. US$0.820267 (per share earnings increased 6.8%)
• Net Profit Margin (Trailing 12 Months vs. Prior Year): 30.5% vs. 30.1% (margin edged up 0.4 percentage points)

Earnings tell part of the story, but investors who care about valuation usually pay close attention to the cash that actually comes through the business. Looking at Utah Medical Products' cash flows alone, the stock could be a whopping 30% undervalued.

Utah Medical Products and the Quiet Bull Case

For a stock often framed as a defensive med tech supplier, Utah Medical Products just gave that view some support. Revenue slipped 12.1%, yet net income and EPS both moved higher, which points to firm cost control and pricing discipline. The trailing 12 month margin nudged up to 30.5%, reinforcing the idea of a resilient, consumables heavy model. Short term price weakness over the past month contrasts with these steady economics, which keeps the narrative of a reliable, cash generative healthcare business intact for now.

Where The Bearish Story Still Holds Up

The cautious angle has plenty to work with. A 12.1% drop in quarterly revenue is uncomfortable for any medical device manufacturer, even if earnings improved. That tilt toward margin preservation over top line momentum can feed worries about procedure volumes or competitive pressure. The share price has drifted down roughly 1% over 30 days and about 0.4% over the past week, which suggests investors are not rushing to reward stronger profitability while the sales line moves the other way.

After a 12.1% revenue drop and multi year earnings erosion, it is fair to ask whether Utah Medical Products is facing deeper structural issues beneath the surface. Review the independent risk analysis for Utah Medical Products which shows 1 important warning sign

Hunt For Quiet Mispricings

Utah Medical Products just showed how earnings resilience and short term share price softness can coexist. The real opportunity is finding stocks that could be undervalued before the market reassesses them.

• Company 1 - 45% below our estimate - expands a Pacific banking footprint by folding in a new franchise while prioritizing a conservative credit culture.
• Company 2 - 25% below our estimate - sells injectable weight loss and diabetes drugs that recently converged into a single product family driving strong demand.
• Company 3 - 42% below our estimate - builds protective films and coatings while directing fresh capital into a manufacturing and supply chain expansion.

Three companies from the same screener. Open all 27 potentially undervalued companies →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com